The effects of atrial natriuretic peptide were investigated on water and electrolyte transport in the human jejunum. Six healthy male volunteers (aged 21-33 years) were studied using a triple lumen perfusion technique. A plasma like electrolyte solution containing polyethylene glycol (5 g/l) as a non-absorbable marker was perfused into the jejunum at 10 ml/min, and net water and electrolyte transport and transepithelial potential difference were measured. Subjects were studied single blind on two occasions with either intravenous atrial natriuretic peptide (6 pmollminlkg for 90 minutes) or placebo (saline), both after controlled sodium intake over three days. Plasma atrial natriuretic peptide concentrations rose from (mean (SD)) 10-3 (3.6) pmol/l to a peak of 96-0 (61.8) Atrial natriuretic peptide is a hormone which has been found in a variety of species.' The 126-amino acid propeptide is synthesised and stored in atrial myocytes. The most important biologically active natriuretic peptide released into the circulation is a atrial natriuretic peptide, the 99-126 fraction at the C-terminal end. In humans acute volume load with saline, high sodium intake, or conditions with increased extracellular volume such as chronic heart and renal failure, result in increased plasma atrial natriuretic peptide concentrations.2 Intravenously infused synthetic human a atrial natriuretic peptide in normal subjects induces diuresis, natriuresis, and haemoconcentration,`can lower blood pressure,5 and inhibits renin and aldosterone secretion.6 Given these effects, it seems likely that atrial natriuretic peptide has a physiological role in the regulation of sodium balance and extracellular volume. Atrial natriuretic peptide receptors are found in various organs including the jejunum of the rat. 78 The effect of this hormone on small intestinal transport has not been extensively studied and the available data in animals`" and humans'2 are controversial. Our aim was therefore to investigate whether human atrial natriuretic peptide, infused intravenously in doses simulating pathophysiological blood concentrations, has an effect on water and electrolyte transport in the human jejunum using the triple lumen perfusion technique.
Atrial natriuretic peptide is a hormone which has been found in a variety of species.' The 126-amino acid propeptide is synthesised and stored in atrial myocytes. The most important biologically active natriuretic peptide released into the circulation is a atrial natriuretic peptide, the 99-126 fraction at the C-terminal end. In humans acute volume load with saline, high sodium intake, or conditions with increased extracellular volume such as chronic heart and renal failure, result in increased plasma atrial natriuretic peptide concentrations.2 Intravenously infused synthetic human a atrial natriuretic peptide in normal subjects induces diuresis, natriuresis, and haemoconcentration,`can lower blood pressure, 5 and inhibits renin and aldosterone secretion.6 Given these effects, it seems likely that atrial natriuretic peptide has a physiological role in the regulation of sodium balance and extracellular volume. Atrial natriuretic peptide receptors are found in various organs including the jejunum of the rat. 78 The effect of this hormone on small intestinal transport has not been extensively studied and the available data in animals`" and humans'2 are controversial. Our aim was therefore to investigate whether human atrial natriuretic peptide, infused intravenously in doses simulating pathophysiological blood concentrations, has an effect on water and electrolyte transport in the human jejunum using the triple lumen perfusion technique.
Methods
Six normal male volunteers aged 21-33 years (mean 24 years) were studied. Informed written consent was obtained from all subjects and the study protocol was approved by the Otago Hospital Board Ethics Committee.
STUDY PROTOCOL
Each subject was studied on two separate occasions at least one week apart, once with intravenous atrial natriuretic peptide and once with placebo. The subjects were on a specially composed diet with fixed sodium and potassium intakes of 150 and 70 mmol/day respectively for three days before each study. They were not admitted to hospital for this period. On the third day of the diet a 24 hour urine collection was made to measure electrolyte excretion and creatinine clearance. One subject did not complete the 24 hour collection on one occasion and all his urine baseline data for both tests were excluded from the final analysis. On the fourth day the volunteers were intubated with the intestinal perfusion tube at 0700 hours after an overnight fast. They then remained supine for the rest of the study, apart from brief periods of standing to pass urine. One intravenous cannula was inserted in each arm, one for blood sampling and the other for intravenous atrial natriuretic peptide/placebo infusion. A subcutaneous cannula was placed in one arm for potential difference measurements. The study consisted of a first control period (60 minutes, time -60 to 0), the active period ( (Fig 1) . Plasma osmolality and plasma electrolytes remained normal throughout the study and there was no difference between active and control days. While the haematocrit dropped slightly during the control studies, it steadily increased after starting the atrial natriuretic peptide infusion and was significantly higher at the end of the study (Fig 1) . The failure. '9 20 In the jejunum atrial natriuretic peptide receptors are localised in the mucosa beneath the columnar epithelium in the area of the villi but not the crypts,721 suggesting a possible influence on the absorptive properties of this intestinal segment. Published data on the effects of atrial natriuretic peptide on small intestinal transport are controversial. In rats some workers have shown increased8 and some decreased922 effects on net absorption. In our own studies in rats23 we showed that pharmacological doses (raising plasma concentrations by a factor of 130) had no effect on jejunal transport or colonic electrical parameters; however, even larger doses (raising plasma concentrations by a factor of over 1400) decreased net absorption and even induced secretion in the jejunum, but had no effect on the colon. This effect may well have been a nonspecific or even 'toxic' response.
The only study of human transport, by Petritsch et al,'2 investigated both the jejunum and the ileum. The data gained from the jejunum are in agreement with our findings. In that study, however, the subjects were investigated on only one occasion and did not have a control perfusion with placebo infusion on a separate day. Since perfusions constitute an intestinal volume load, this itself could stimulate endogenous atrial natriuretic peptide secretion. In our study plasma concentrations remained unchanged during control perfusions, indicating that the net intestinal saline load of 10 ml/min was not enough to release endogenous atrial natriuretic peptide. Petritsch et al'2 also reported similar plasma concentrations at the beginning and end oftheir perfusion period, which mitigates against appreciable volume load. It seems possible that more pronounced volume loading, especially together with the application of exogenous atrial natriuretic peptide, may decrease net intestinal absorption.
Blood volume expansion, a known stimulus to atrial natriuretic peptide release, decreased sodium and water absorption in the dog24 and the rat.922 A c-GMP mediated atrial natriuretic peptide effect, previously reported in rats,25 might be involved. In humans intravenous infusion increased plasma concentrations of c-GMP and increased urinary c-GMP excretion.26 Tissue c-GMP released into the extracellular space27 should be detectable in jejunal aspirates; however, we were unable to show differences in jejunal c-GMP output between atrial natriuretic peptide and control studies (Table III ). In contrast, urinary c-GMP excretion increased sixfold to 11-fold during the diuresis accompanying atrial natriuretic peptide infusion (tested in two subjects). This provides convincing evidence of c-GMP mediated bioactivity of the infused atrial natriuretic peptide in the kidneys26 but not in the gut.
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